Pengle Hack Tool V 109
Bran Cardello
Purpose: To conduct a prospective observational study across 12 U.S. hospitals to evaluate real-time performance of an interpretable artificial intelligence (AI) model to detect COVID-19 on chest radiographs.
Conclusion: AI-based tools have not yet reached full diagnostic potential for COVID-19 and underperform compared with radiologist prediction. Keywords: Diagnosis, Classification, Application Domain, Infection, Lung Supplemental material is available for this article.. RSNA, 2022.
All content on this site: Copyright 2024 Elsevier B.V. or its licensors and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply
The researchers focus on exploring the research paradigm of the classic mutp53 model - malignant lymphoma (Figure 2). Through flow cytometry, single cell transcriptome analysis, and clone analysis, they found that pre cancer cells with high accumulation of mutp53 exhibit unique genomic and transcriptome characteristics, and significantly upregulate oncogenes and pathways such as amino acid transport and metabolism. The amino acid transport inhibitor JPH203, which has entered Phase I clinical practice, can be employed to target precancerous cells in the early stage, thus effectively preventing the occurrence of malignant lymphoma.
In summary, this study created mutp53 fluorescent fusion protein reporter gene mice and established various immune normal mouse tumor development models. Through visualization of mutp53 molecular function, low abundance precancerous cells were labeled, traced, and targeted in multiple organ pathological normal tissues, providing an important tool for understanding the evolution and regulatory mechanisms of the early stages of tumor development.
By means of innovative tumor models, combining single cell and spatial multi omics analysis, the Yuan Wang team has studied the occurrence and development mechanisms of solid tumors such as malignant brain tumors, lymphoma, and ovarian cancer, exploring new strategies for early diagnosis and prevention of tumors. In the past five years, they have published papers as corresponding authors (including co authors) in Nature Cancer, Cell Research, Nature Communications, Science Advances,and so forth.
Single-cell RNA sequencing (scRNA-seq), a technology that analyzes transcriptomes of complex tissues at single-cell levels, can identify differential gene expression and epigenetic factors caused by mutations in unicellular genomes, as well as new cell-specific markers and cell types. scRNA-seq plays an important role in various aspects of tumor research. It reveals the heterogeneity of tumor cells and monitors the progress of tumor development, thereby preventing further cellular deterioration. Furthermore, the transcriptome analysis of immune cells in tumor tissue can be used to classify immune cells, their immune escape mechanisms and drug resistance mechanisms, and to develop effective clinical targeted therapies combined with immunotherapy. Moreover, this method enables the study of intercellular communication and the interaction of tumor cells and non-malignant cells to reveal their role in carcinogenesis. scRNA-seq provides new technical means for further development of tumor research and is expected to make significant breakthroughs in this field. This review focuses on the principles of scRNA-seq, with an emphasis on the application of scRNA-seq in tumor heterogeneity, pathogenesis, and treatment.
Malignant tumors are caused by genetic mutations that result from the influence of endogenous and environmental factors, and this challenging aspect of oncology has always been a hot topic in medical research [1, 2]. Tumor development is a complex and multi-stage process whereby normal cells develop into malignant tumors, through a series of multiple gene mutations and accumulation in somatic cells. In normal somatic cells due to several factors, genomic instability among them, mutations replicate and accumulate by repeated proliferation and division processes, with important gene mutations resulting in changes in cell phenotypes. During the development of a variety of tumors, several important gene mutations are common which drive the malignant differentiation of cells, as seen by the limitless proliferation, metastasis, and angiogenesis [3,4,5]. Driver mutation is a key molecular event in tumor occurrence, which affects the degree of malignancy and the prognosis of patients [6]. However, after various divisions and proliferation throughout the process of cell differentiation, the numerous biological or genetic differences within the tumor cells result in the formation of complex tumor heterogeneity [7]. Additionally, tumor tissues differentiate into different cell types and subsets, and develop multiple resistance and proliferation advantages depending on their microenvironments [8,9,10]. Tumor heterogeneity is the main driving force of drug resistance [11].
Tumor microenvironments play an important role in tumor development and heterogeneity [12]. It is the microenvironmental selection force that may determine the optimal phenotypic properties, that is, the cellular characteristics resulting in the greatest fitness [13]. This is seen by tumor cells at the tumor-host interface which exhibit features that promote invasion and metastasis, whereas cells inside the tumor tissue maximize proliferation by promoting metabolism, such as angiogenesis [14, 15]. In tumor microenvironments, except in malignant cells, the composition and the infiltration degree of immune cells in different tumor types are different [16]. When more T cells infiltrate the tumor tissue, the volume of tumor tissues remains smaller [17] and the patients have a better prognosis [18]. At the same time, various other components of tumor tissues, such as macrophages and neutrophils [19], also closely regulate the immune microenvironment of the tumor. Thus, the sensitivity of different individuals to immunotherapy has an extensive heterogeneity [20, 21]. Additionally, all cell types within the tumor microenvironment interact with each other through cellular communication mechanisms, which increase the complexity of tumor development. Understanding these communication processes between tumor cells are crucial for the formulation of effective anticancer immunotherapy strategies [22,23,24].
Tumor heterogeneity plays an important role in cancer progression and it is particularly important to thoroughly understand the gene expression patterns of individual cells [25,26,27]. Common sequencing methods combine thousands of multiple subsets cells for sequencing. So the rare cell clones, which may play an important role in tumor progression, are covered up. It is impossible to accurately track individual cell mutations in the process of tumor progression [28]. Next-generation sequencing (NGS) methods can be used to assess tumor heterogeneity, to track changes within the heterogeneity, and to assess the selective evolution of tumor cells during the course of treatment [11]. Single-cell RNA sequencing (scRNA-seq) overcomes the limitations of traditional RNA sequencing methods, by measuring the whole transcriptome at a single-cell resolution and distinguishing different cell types in tumor tissue. Moreover, this enables a clearer understanding of the molecular mechanisms promoting tumor occurrence, and reveals the somatic mutations throughout the course of tumor evolution [29]. scRNA-seq of tumors at different time points can identify key gene mutations, as well as the dynamic change of the tumor heterogeneity over time. Additionally, this method enables the monitoring of rare cell mutations during processes of tumor occurrence and development, such as the acquisition of invasive and metastatic abilities, as well as the infiltration and activation of immune cells and other important processes [30]. scRNA-seq can also be combined with immune checkpoint therapy to specifically detect the transcriptional activity of immune checkpoints, or to specifically screen neoantigens with high transcription levels [31, 32]. Research on scRNA-seq technologies have seen a significant increase in the last few years, thereby providing new opportunities and strategic approaches for the clinical treatment of cancer. With the development of sequencing technology, the sensitivity and accuracy of detection are gradually improving, and the cost is gradually reducing; thus scRNA-seq has become an important technical tool in tumor research. This review focuses on scRNA-seq, with emphasis on the application of scRNA-seq in tumor heterogeneity, pathogenesis, and treatment.
It is not possible to sequence RNA directly from single cells. Therefore, scRNA-seq must first convert RNA into cDNA and amplify it by polymerase chain reaction (PCR) or by in vitro transcription (IVT) before subsequent sequencing [33]. There are two main problems with this process: first, the loss of RNA must be minimized during reverse transcription; second, amplification should produce enough DNA for sequencing and control the impact of non-single-cell noise [34]. To address these shortcomings, several generations of scRNA-seq technologies are being innovated and improved to adapt to the expanding research scope. scRNA-seq technology has unique advantages and applicable detection content.
Generally, the scRNA-seq consists of four steps:(1) isolation of single cells, (2) reverse transcription, (3) cDNA amplification, and (4) sequencing library construction [34](Fig. 1). Isolation of single cells mainly includes cell selection, random seeding/dilution, laser microdissection (LCM), fluorescence-activated cell sorting (FACS), and microfluidic/microplate methodology [35, 36]. FACS is the most commonly used method. Manual cell selection is used during the early stage [37], however, the isolation efficiency is low. Microfluidic technology is applied in Drop-seq to wrap a single-cell into an independent microdroplet, which includes oligonucleotide primers, unique molecular identifiers (UMI), DNA bases and cells(Fig. 1). Microfluidic technology considerably increases the single-cell catch and library capacity, thereby enabling thousands of cells to be analyzed simultaneously; therefore, highlighting a great advantage of this method to screen large numbers of cells for sequencing [38, 39].
b37509886e